<< Back
Printer Friendly Version View printer-friendly version
BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum

ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 21, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Adi Mohanty will participate in a panel discussion at Cell & Gene Therapy CEO on Monday, September 25, 2017 in Boston.

The panel, titled “Financing Innovation: Attracting Investment” is at 2:00pm ET/11:00am PT. The discussion will be moderated by Rich Daly, Chairman and CEO of Neuralstem. Panelists include Mark Barrett, Entrepreneur-in-Residence, Frazier Healthcare Partners, David Grainger, Ph.D., CEO of Methuselah Health and Partner at Medicxi, and Nora Yang, Director, Portfolio Management & Strategic Operations at the National Center for Advancing Translational Sciences, National Institutes of Health.

Cell & Gene Therapy CEO is an off-the-record networking forum that brings together CEOs and decision makers in cell therapy, gene therapy, and regenerative medicine. Intimate discussion panels, keynotes and fireside chats feature thought leaders debating business model efficiencies, financing, regulatory issues, market access and reimbursement, novel partnerships, manufacturing, and delivery challenges. Healthcare investors and leading researchers also participate.

About BioTime

BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of the Company’s cell delivery platform is its HyStem® cell and drug delivery matrix technology. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, and one private company, AgeX Therapeutics.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on TwitterLinkedInFacebookYouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotimeinc.com.

Source: BioTime, Inc.

Investor Contact:
BioTime
David Nakasone 510-871-4188
DNakasone@biotimeinc.com
or
Media Contact for BioTime
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com